Hormonal
Administration of the highly proliferative probiotic strain Bifidobacterium animalis ssp. lactis GCL2505 (BlaG) ameliorates metabolic disorders, specifically improving glucose tolerance and reducing visceral fat accumulation, by modulating gut microbiota to elevate acetate levels and subsequently increasing glucagon-like peptide-1 (GLP-1) secretion.
If you are looking to use probiotics to support metabolic health, specifically glucose control and fat management, the specific strain matters significantly. This research suggests that Bifidobacterium animalis ssp. lactis GCL2505, taken daily at 1 billion CFU, may help improve glucose tolerance and reduce visceral fat in the context of a high-fat diet by increasing gut acetate and GLP-1. However, this was observed in mice, and human results may vary. It highlights that 'proliferative' strains might be more effective than non-proliferative ones for these specific outcomes.
These findings indicated that BlaG, a highly viable and proliferative probiotic, improves metabolic disorders by modulating gut microbiota, which results in the elevation of SCFAs, especially acetate.
Why this rating
The study is a controlled animal experiment (mice) with clear statistical significance, but lacks human clinical trial data.
Source
A proliferative probiotic Bifidobacterium strain in the gut ameliorates progression of metabolic disorders via microbiota modulation and acetate elevation
Ryo Aoki et al. · Scientific Reports · 2017
DOI 10.1038/srep43522
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →